When investigators talk about the liver fat evidence for tesamorelin, they mean Stanley's 2014 paper in JAMA — full stop. It was the first randomised controlled trial to measure hepatic fat fraction directly using proton magnetic resonance spectroscopy (1H-MRS), not the surrogate of visceral fat alone. The result — a 32% relative reduction in liver fat — moved tesamorelin from a visceral adipose tissue (VAT) peptide into a molecule with a credible hepatic lipid mechanism. This post breaks down what the investigators did, what they measured, what the numbers mean, and how the study fits into the broader tesamorelin evidence ladder from Falutz 2007 all the way to Stanley 2019. If you want to buy tesamorelin UAE for research, understanding this literature is the starting point. REVIVE LAB UAE is the peptides UAE supplier that keeps both 5 mg and 10 mg vials in cold-chain stock for same-day dispatch across Dubai and next-day delivery across the other six emirates.
The 2014 JAMA trial enrolled 50 HIV-infected men with both abdominal fat accumulation and radiologically confirmed NAFLD. Investigators randomised subjects 1:1 to tesamorelin 2 mg SC daily or matching placebo for 6 months. The primary endpoint was change in hepatic fat fraction measured by 1H-MRS — a well-validated, radiation-free imaging technique that quantifies fat within the liver parenchyma with precision unavailable to standard ultrasound.
| Endpoint | Tesamorelin Group | Placebo Group | Significance |
|---|---|---|---|
| Hepatic fat fraction change | −32% (relative) | +11% (relative) | p = 0.01 |
| NAFLD responders (≥30% reduction) | 35% | 4% | p = 0.003 |
| Visceral adipose tissue (VAT) | Significant reduction | No change | p < 0.001 |
| IGF-1 levels | Elevated (expected) | Unchanged | Consistent with mechanism |
| Liver enzymes (ALT/AST) | Trend toward improvement | No change | Not primary endpoint |
The "NAFLD responder" analysis is particularly striking: 35% of tesamorelin subjects achieved a 30% or greater reduction in liver fat, compared to just 4% on placebo. Investigators also noted that subjects who were NAFLD responders at six months also showed larger reductions in VAT — suggesting the hepatic and visceral fat effects are mechanistically linked rather than independent.
Earlier tesamorelin research relied on CT or DXA for visceral fat quantification. Stanley's group upgraded the methodology for this trial. Proton MRS can detect hepatic fat fractions as low as 1-2% and track changes too small for CT or ultrasound to resolve reliably. This is not a trivial upgrade — it means the -32% figure is likely an underestimate of the true biological signal in high-responders, because the technique is precise enough to capture even modest improvements without noise diluting the effect size. Investigators who want to replicate this measurement paradigm in future research protocols will need access to exactly the same peptide purity standards — which is where supplier quality matters.
Tesamorelin is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH 1-44) with a trans-3-hexenoyl modification at the N-terminus. This structural tweak confers resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage — the enzyme that normally degrades native GHRH within minutes of secretion — extending the effective half-life and enabling sustained receptor engagement at the pituitary somatotroph.
When tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, it amplifies the natural pulsatile release of growth hormone (GH). This matters because GH acts directly on adipocytes via hormone-sensitive lipase (HSL) activation — promoting lipolysis and reducing de novo lipogenesis. The hepatic fat reduction in the Stanley trial is consistent with two concurrent mechanisms:
The result is a dual mechanism that attacks hepatic steatosis from both sides: less fat arriving from visceral depots, and more fat burned within the hepatocyte itself. IGF-1 elevation (roughly +50% in the Falutz 2007 NEJM trial) is a downstream consequence, not the primary driver — though IGF-1 itself has hepatocyte-protective properties at physiological concentrations.
No single trial is read in isolation. Tesamorelin's NAFLD data gains its credibility from a consistent evidence ladder across four major publications:
| Publication | N | Duration | Key Finding |
|---|---|---|---|
| Falutz et al. 2007 — NEJM | 412 | 26 weeks | VAT −15–18% vs placebo; IGF-1 +~50%; established VAT selectivity |
| Falutz et al. 2010 — Extension | Subset | 26-week extension (52 wk total) | VAT reduction maintained through 52 weeks; no evidence of lipohypertrophy rebound during treatment |
| Stanley et al. 2014 — JAMA | 50 | 24 weeks | Liver fat −32% by 1H-MRS; 35% NAFLD responders vs 4% placebo |
| Stanley et al. 2019 — Lancet HIV | 61 | 52 weeks | NAFLD reduction sustained at 12 months; VAT benefit maintained; safety profile consistent |
The Falutz 2007 NEJM trial was the landmark — 412 subjects, the largest tesamorelin RCT to date — and it established the visceral fat selectivity that makes tesamorelin distinct from GH itself (which causes more diffuse fat redistribution and worse glucose-related side effects). Stanley's 2014 work then used this VAT mechanism to make a testable prediction about hepatic fat, which was confirmed. The 2019 Lancet HIV extension demonstrated durability at 12 months. Across all four studies, the dosing protocol in the active arm is consistent: tesamorelin 2 mg/day, subcutaneous, once daily.
Research protocols across the Falutz and Stanley programmes used a consistent administration scheme. Investigators in the UAE replicating these designs would reference the following parameters:
| Parameter | Research Context Value | Notes |
|---|---|---|
| Standard research dose | 2 mg/day SC | Used in Falutz 2007, 2010 and Stanley 2014, 2019 |
| Lower-dose investigative range | 1 mg/day SC | Referenced in some investigator frameworks for shorter windows |
| Vial sizes available (REVIVE LAB UAE) | 5 mg / 10 mg | Only available strengths — no 1 mg or 2 mg vials stocked |
| Reconstitution volume (5 mg vial) | 1–2.5 mL BAC water | 2.5 mL gives 2 mg/mL; 1 mL gives 5 mg/mL |
| Reconstitution volume (10 mg vial) | 2–5 mL BAC water | 5 mL gives 2 mg/mL matching trial concentration |
| Storage (lyophilized) | 2–8°C, protected from light | Stable ≥30 days from opening |
| Storage (reconstituted) | 2–8°C | Use within 7–14 days |
The convenience of a 10 mg vial becomes apparent when running a 2 mg/day research protocol — a single vial, reconstituted with 5 mL BAC water to give 2 mg/mL, provides exactly five research administrations of 1 mL each, matching the Stanley trial concentration precisely. REVIVE LAB UAE stocks both vial sizes with HPLC purity documentation on every lot. Researchers can order tesamorelin UAE directly from stock with same-day dispatch to Dubai neighbourhoods or tesamorelin 24h delivery to any other emirate.
The 2014 JAMA trial left a critical open question: does the liver fat reduction hold at 12 months, or does the liver simply adapt to GH stimulation and revert? Stanley's group answered this in 2019 in Lancet HIV, enrolling 61 HIV-infected subjects and tracking hepatic fat fraction through 52 weeks.
The key findings from the 2019 extension are:
For researchers designing longer-duration protocols, the 2019 Lancet HIV paper is now the reference for 12-month safety and efficacy data. The 2014 JAMA paper remains the foundational mechanistic reference for hepatic fat specifically.
The research value of tesamorelin is only realisable if the molecule arrives at the bench in the condition the Stanley and Falutz groups maintained in their clinical facilities. That requires three things: verified purity, continuous cold chain, and a supplier that understands peptide stability. REVIVE LAB UAE was built around exactly this. Every tesamorelin batch is HPLC-tested to ≥99% purity with lot-specific certificates of analysis available on request. Vials are cold-chain dispatched in validated insulation that holds 2–8°C through any UAE summer transit — whether to a Dubai Marina research facility or a laboratory in Fujairah.
Delivery coverage across all seven emirates:
| Emirate / Area | Delivery Window | Cash on Delivery |
|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Downtown, Palm, Jumeirah) | Same day, 4–8 hours | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | 24 hours | Yes |
| Sharjah | Same day / 24 hours | Yes |
| Ajman | 24 hours | Yes |
| Ras Al Khaimah | 24 hours | Yes |
| Fujairah | 24 hours | Yes |
| Umm Al Quwain | 24 hours | Yes |
REVIVE LAB UAE is not a reseller or freight-forwarder. It is a UAE-based peptides supplier with physical cold-chain infrastructure and tesamorelin in stock at the point of dispatch. Tesamorelin in stock UAE means orders placed before the daily cut-off ship the same day — not "3–5 business days from a foreign warehouse." For researchers in Dubai who need peptides UAE on a tight protocol timeline, the difference is not trivial. REVIVE LAB UAE also supports tesamorelin cash on delivery Dubai across all areas of the emirate, including Business Bay, DIFC, JBR, JVC, Jumeirah, Palm Jumeirah, Downtown, Emirates Hills, Arabian Ranches, and Mirdif.
Stanley et al. (JAMA, 2014) conducted a randomised, double-blind, placebo-controlled trial in 50 HIV-infected subjects with non-alcoholic fatty liver disease (NAFLD). Investigators found that tesamorelin at 2 mg/day SC reduced hepatic fat fraction by approximately 32% relative to placebo after 6 months of research-context administration, as measured by proton magnetic resonance spectroscopy (1H-MRS). Visceral adipose tissue (VAT) also decreased significantly, consistent with the Falutz 2007 and 2010 NEJM findings. These results were later extended to 12 months in the Stanley 2019 Lancet HIV trial, which confirmed durability of the hepatic fat reduction.
REVIVE LAB UAE supplies HPLC-verified tesamorelin in 5 mg and 10 mg vials — the two strengths relevant to published research protocols. The Stanley 2014 JAMA and Stanley 2019 Lancet HIV protocols used 2 mg/day SC; the Falutz 2007 NEJM and 2010 extension used the same dose. Some investigator frameworks reference 1 mg/day for exploratory or shorter-window research designs. REVIVE LAB UAE vials are lot-COA documented, cold-chain dispatched across all seven emirates, and available with tesamorelin same day Dubai delivery and tesamorelin 24h delivery UAE-wide.
Yes. REVIVE LAB UAE offers tesamorelin same day Dubai delivery for orders placed before the daily dispatch cut-off, and tesamorelin Dubai 24h delivery across Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. All shipments are cold-chain insulated, HPLC-verified with lot-COA, dispatched in discreet unbranded outer packaging, and eligible for tesamorelin cash on delivery Dubai across all delivery areas. Visit /buy-tesamorelin-uae/ to place an order.